Individualized Comprehensive Therapy for the Lung Cancer Patients
with HIV Infection.
10.3779/j.issn.1009-3419.2018.04.21
- Author:
Lin WANG
1
;
Yanzheng SONG
1
Author Information
1. Department of Cerebral Surgery Public Health Clinical Center Affiliated, Shanghai 201508, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Human immunodeficiency virus;
Individualized;
Lung neoplasms;
Surgical treatment;
Survival rate
- MeSH:
Adult;
Aged;
Anti-HIV Agents;
therapeutic use;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Antiretroviral Therapy, Highly Active;
Female;
HIV Infections;
complications;
drug therapy;
mortality;
Humans;
Lung Neoplasms;
complications;
drug therapy;
mortality;
surgery;
Male;
Middle Aged;
Neoplasm Staging;
Retrospective Studies;
Survival Rate
- From:
Chinese Journal of Lung Cancer
2018;21(4):327-332
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:To observe clinical features, clinical stagings, types ofpathology, treatment options and clinical effects of patients suffer from HIV infection combined with lung cancer, and also to provide guidance for individualized comprehensive treatment of HIV combined with lung cancer.
METHODS:Through the retrospective analysis of 53 cases of HIV merger of lung cancer patients admitted in our department, 47 cases of non-small cell lung cancer (NSCLC), 6 cases of small cell lung cancer (SCLC), 24 cases accepted surgery combined chemotherapy, 22 patients with simple chemotherapy, 7 cases give up treatment; 28 cases are in stages I-III, 25 cases are in stage IV; 24 patients received combined chemotherapy in 28 patients with stages I-III, 2 cases gave up treatment, 2 cases with severe chronic obstructive pulmonary disease (COPD) could not tolerate chemotherapy plus surgery. According to the situation of patients before highly active anti-retroviral therapy (HAART) treatment, patients who received HAART before treatment were divided into observation group (n=27), patients who did not receive HAART were divided into control group (n=19). The survival and the independent influencing factors between the two groups were analyzed.
RESULTS:Among the 53 HIV infected cases a toal of 46 patients received treatment among 53 cases of treatment in patients with lung cancer merger of HIV, there are no differences of 1 year survival rate, 2 years survival rate between observation group and control group; patients in I-III phase 1 year survival rate was 76.0%, 2 years survival rate was 60.0%. Patients in IV phase 1 year survival rate was 13.6%, 2 years survival rate was 0%. 24 patients with surgery combined chemotherapy 1 year survival rate was 83.3%, 2 years survival rate was 62.5%; 22 cases treated with simple chemotherapy 1 year survival rate was 18.0%, 2 years survival rate was 0%.
CONCLUSIONS:HIV merger in patients with lung cancer can improve the patients survival rate after different individualized comprehensive treatment, early surgery with combined chemotherapy has remarkable effect.
